Stay Informed about Small Business

<!– –> <!– Page Last Updated: 09/20/2011 –> Page Last Updated: 09/20/2011 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.

Comunicado de Seguridad de Medicamentos de la FDA: Ritmos cardíacos anormales asociados con dosis altas de Celexa (bromhidrato de citalopram)

Anuncio de seguridadInformación adicional para pacientesInformación adicional para profesionales de la saludResumen de Datos Anuncio de seguridad El 24 de agosto de 2011 la Administración de Alimentos y Medicamentos de los EE. UU. (FDA) informó a los profesionales de la salud y los pacientes que el antidepresivo Celexa (bromhidrato de citalopram, también comercializado como genérico)…

FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFα) blockers now include warnings about infection with Legionella and Listeria bacteria

Safety Announcement Additional Information for Patients Additional Information for Healthcare Professionals Data SummaryReferences   Safety Announcement [9-07-2011] The U.S. Food and Drug Administration (FDA) is informing healthcare professionals that the Boxed Warning for the entire class of Tumor Necrosis Factor-alpha (TNFα) blockers has been updated to include the risk of infection from two bacterial pathogens,…

FDA Drug Safety Communication: Serious allergic reactions reported with the use of Saphris (asenapine maleate)

Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare ProfessionalsData Summary References   Safety Announcement [09-01-2011] The U.S. Food and Drug Administration (FDA) is warning the public that serious allergic reactions have been reported with the use of the antipsychotic medication Saphris (asenapine maleate). The Contraindications, Warnings and Precautions, Adverse Reactions, and Patient Counseling Information sections…

FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide)

Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare ProfessionalsData Summary    Safety Announcement [8-24-2011] The U.S. Food and Drug Administration (FDA) is informing healthcare professionals and patients that the antidepressant Celexa (citalopram hydrobromide; also marketed as generics) should no longer be used at doses greater than 40 mg per day because it can cause abnormal…

Comunicado de Seguridad de Medicamentos de la FDA: Informes sobre un efecto adverso raro pero grave y potencialmente fatal del uso de benzocaína en gel o líquido de venta libre que se aplica a las encías o la boca

Anuncio de seguridadInformación adicional para pacientesInformación adicional para profesionales de la saludResumen de Datos   Anuncio de seguridad  El 7 de abril de 2010 la Administración de Alimentos y Medicamentos de los EE.UU. (FDA) alertó al público que el uso de benzocaína, el ingrediente principal de muchos geles y líquidos de venta libre que se…